• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

GFAP Antibody – Mouse Monoclonal

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS670163

MBS670163 is an antibody targeting GFAP. Also known as Mouse Anti-Human GFAP-CY3. Reactive in Human. Host: Mouse. More details

DISCONTINUED
Click here to view our similar product(s) OR click here to contact our technical support team for suitable replacement.
Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Product Name
GFAP, Monoclonal Antibody
Full Product Name
Mouse Anti-Human GFAP-CY3
Product Gene Name
Product Synonym Names
Mouse Anti-Human GFAPCyanine3-Labeled; Mouse Anti-Human GFAP
Clonality
Monoclonal
Isotype
Mouse (BALB/c) IgG2b, kappa
Clone Number
SB61b1
Host
Mouse
Species Reactivity
Human
Form/Format
Cyanine 3 (CY3) Conjugate
Specificity
Reacts with human GFAP (~ 50 kDa)1
Glial Fibrillary Acid Protein (GFAP) was discovered by Bignami et al 2 as a major fibrous protein of multiple sclerosis plaques. It was subsequently found to be a member of the 10 nm or intermediate filament protein family, specifically the intermediate filament protein family Class III, which also includes peripherin, desmin and vimentin. GFAP is heavily, and specifically, expressed in astrocytes and certain other astroglia in the central nervous system, in satellite cells in peripheral ganglia, and in non-myelinating Schwann cells in peripheral nerves.3 Many types of brain tumors, presumably of astrocytic origin, heavily express GFAP. In addition, neural stem cells frequently strongly express GFAP. It is also found in the lens epithelium, Kupffer cells of the liver, in some cells of salivary tumors, and has been reported in erythrocytes. Therefore, antibodies to GFAP are very useful as markers of astrocytic cells and neural stem cells, and for distinguishing neoplasms of astrocytic origin from other neoplasms in the central nervous system.
Although its function is not fully understood, GFAP protein is probably involved in controlling the shape and movement of astrocytes. The protein may also play a significant role in the interactions of astrocytes with other cells, which are required for the formation and maintenance of the myelin layer that covers nerve cells. Additionally, GFAP may assist in maintaining the protective blood-brain barrier.
In adults, GFAP levels increase as a result of the proliferation of astrocytes that occurs in response to a variety of physical, chemical and etiological insults, including Alzheimer's disease, epilepsy and multiple sclerosis. Alexander's disease was recently shown to be caused by point mutations in the protein-coding region of the GFAP gene.4 All forms of Alexander's disease are characterized by the presence of Rosenthal fibers, which are GFAP-containing cytoplasmic inclusions found in astrocytes.
Preparation and Storage
The purified (UNLB) antibody is supplied as 0.5 mg purified immunoglobulin in 1.0 mL of 100 mM borate buffered saline, pH 8.0; store at 2-8 degree C.
HRP conjugate is supplied in 1.0 mL of stock solution in 50% glycerol/50% phosphate buffered saline, pH.7.4. No preservative added. Store at 2-8 degree C or long-term at -20 degree C.
The biotin (BIOT) conjugate is supplied as 0.5 mg in 1.0 mL PBS/NaN3. Store at 2-8 degree C.
Reagents are stable for the period shown on the label if stored as directed.
Molecular Weight
49,880 Da
Chromosome Location
chromosome: 17; Location: 17q21
OMIM
137780
3D Structure
ModBase 3D Structure for P14136
Immunogen
Recombinant human Glial Fibrillary Acid Protein (GFAP)
Characterization
To ensure acceptable performance, each batch of product is tested by immunohistochemistry and Western blotting to conform to characteristics of a standard reference reagent.
Applications Tested/Suitable for anti-GFAP antibody
Immunohistochemistry; Western Blot
Application Notes for anti-GFAP antibody
Research Application(s): Immunohistochemistry (FS or cultured and methanol-fixed cell lines)

Western Blot Suggested Dilution: 1ug/mL

Testing Data of anti-GFAP antibody

Mouse Anti-GFAP Monoclonal Antibody – Cat# MBS670163

Product References and Citations for anti-GFAP antibody

1) Lukas, Z. et al. 1989. Expression of vimentin and glial fibrillary acid protein in human developing spinal cord. Histochem. J. 21:693.
3) Brenner, M. et al. 2001. Mutations in GFAP, encoding glial fibrillary acid protein, are associated with Alexander's Disease. Nat. Genet. 7:118-120.

Other Notes

Small volumes of anti-GFAP antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Additional Details

NCBI/Uniprot data below describe general gene information for GFAP. It may not necessarily be applicable to this product.

NCBI GI #
NCBI GeneID
UniProt Primary Accession #
UniProt Secondary Accession #
UniProt Related Accession #
NCBI Official Full Name
glial fibrillary acidic protein
NCBI Official Synonym Full Names
glial fibrillary acidic protein
NCBI Official Symbol
GFAP
NCBI Official Synonym Symbols
FLJ45472; GFAP
UniProt Protein Name
Glial fibrillary acidic protein
UniProt Gene Name
GFAP
UniProt Entry Name
GFAP_HUMAN
NCBI Protein Information
glial fibrillary acidic protein

NCBI Summary for GFAP

This gene encodes one of the major intermediate filament proteins of mature astrocytes. It is used as a marker to distinguish astrocytes from other glial cells during development. Mutations in this gene cause Alexander disease, a rare disorder of astrocytes in the central nervous system. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq]
Show more

UniProt Comments for GFAP

Function: GFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells.

Subunit structure: Interacts with SYNM

By similarity. Isoform 3 interacts with PSEN1 (via N-terminus). Ref.15

Subcellular location: Cytoplasm. Note: Associated with intermediate filaments. Ref.15

Tissue specificity: Expressed in cells lacking fibronectin. Ref.3

Post-translational modification: Phosphorylated by PKN1. Ref.17

Involvement in disease: Defects in GFAP are a cause of Alexander disease (ALEXD) [

MIM:203450]. Alexander disease is a rare disorder of the central nervous system. It is a progressive leukoencephalopathy whose hallmark is the widespread accumulation of Rosenthal fibers which are cytoplasmic inclusions in astrocytes. The most common form affects infants and young children, and is characterized by progressive failure of central myelination, usually leading to death usually within the first decade. Infants with Alexander disease develop a leukoencephalopathy with macrocephaly, seizures, and psychomotor retardation. Patients with juvenile or adult forms typically experience ataxia, bulbar signs and spasticity, and a more slowly progressive course. Ref.19 Ref.20 Ref.21 Ref.22 Ref.23 Ref.24

Sequence similarities: Belongs to the intermediate filament family.
Show more

Research Articles on GFAP

1. This protein has been found differentially expressed in thalami from patients with schizophrenia.
2. Data demonstrate that withaferin A covalently binds soluble recombinant tetrameric human GFAP at cysteine 294.
3. GFAP+1 expressing astrocytes may have a specific role in Alzheimer's disease
4. Results identified glial fibrillary acidic protein that showed elevated levels of protein carbonyls in inferior parietal lobule (IPL) from subjects with early stage-Alzheimer's disease.
5. Determination of relative levels of MBP and GFAP mRNAs may be useful for glial tumors recognition.
6. GFAP-delta may be a useful diagnostic marker for the evaluation of functional cataplasia or proliferation of astrocytic tumor.
7. GFAP is a potential marker for tumors with cartilaginous differentiation.
8. Novel variant (S398F) in the glial fibrillary acidic protein gene is found in a patient with Alexander disease.
9. GFAP-delta is expressed in a variety of pathologies associated with epilepsy, increased expression is shown in regions of astrocytic gliosis
10. GFAP had higher mean expression levels across regions in all psychiatric groups relative to normal control.
11. the best immunohistochemical markers useful for the evaluation of tumors with chordoid morphology were D2-40, EMA, cytokeratin, and GFAP. D2-40 was a true chondroid marker to be useful for the differential diagnosis with chordoma
12. our cell transfection data do indicate that the p.Glu223Gln change has an effect on GFAP polymerization, albeit a modest one
13. Population variation in GFAP with varying Alzheimer lesion burdens suggests that they are not the only driver for astrogliosis
14. NFI family of transcription factors plays a key role in the regulation of both the B-FABP and GFAP genes in malignant glioma cells.
15. This study indicates that the mechanism of GFAP aggregation depends on the domain in which the point mutation(R239C and R416W) is located.
16. Data show tha GFAP levels are significantly higher in intracerebral hemorrhage patients than in ischemic stroke patients.
17. EAAT-1 is superior to GFAP as a helpful diagnostic tool for cancer in choroid plexus samples
18. This protein has been found differentially expressed in the Wernicke's Area from patients with schizophrenia.
19. In Alexander disease mouse models that loss of Cryab results in increased mortality, whereas elevation of Cryab rescues animals from terminal seizures.
20. Downregulated by cytomegalovirus IE1 and IE2 proteins during HCMV infection in U373MG cell line.
Show more

Precautions

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

Disclaimer

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.

Product Note

Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual, it is intended to serve as an example only. Please refer to the instructions For Use provided with the assay kit for precise details.

Product PubMed Publications

Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000